专利检索 ap:("Zhaoning Zhu" OR "Xianhai Huang" OR "Anandan Palani" OR "William J. Greenlee" OR "Robert G. Aslanian") AND inv:"Xianhai Huang" 第 7 页

61.

发明申请
GAMMA SECRETASE MODULATORS 有权
标题翻译： GAMMA秘密调节器

公开(公告)号：US20110294784A1

公开(公告)日：2011-12-01

申请号：US13140987

申请日：2009-12-18

申请人： Theodros Asberom , Xianhai Huang , Zhaoning Zhu , John Clader , Dmitri Pissarnitski , Hubert Josien , Hongmei Li

发明人： Theodros Asberom , Xianhai Huang , Zhaoning Zhu , John Clader , Dmitri Pissarnitski , Hubert Josien , Hongmei Li

IPC分类号： A61K31/553 , A61P27/00 , A61P25/28 , A61P9/10 , C07D498/04 , A61P25/00

CPC分类号： C07D498/04

摘要： This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

摘要翻译： 本发明提供了作为γ分泌酶调节剂的新型化合物。这些化合物具有式（化学式应该插在这里，如纸上所示）。还公开了使用式（I）化合物调节γ-分泌酶活性和治疗阿尔茨海默病的方法的方法。

62.

发明授权
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties 有权

公开(公告)号：US09676780B2

公开(公告)日：2017-06-13

申请号：US14655572

申请日：2013-12-20

申请人： MERCK SHARP & DOHME CORP. , Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

发明人： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC分类号： C07D487/04 , A61K31/519 , C07D487/08 , C07D487/18 , C07D513/04

CPC分类号： C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

摘要： Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

63.

发明申请
NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS 有权

公开(公告)号：US20230008022A1

公开(公告)日：2023-01-12

申请号：US17295497

申请日：2019-11-25

申请人： Dane CLAUSEN , Ping CHEN , Xavier FRADERA , Liangqin GUO , Yongxin HAN , Shuwen HE , Xianhai HUANG , Joseph KOZLOWSKI , Guoqing LI , Theodore A. MARTINOT , Alexander PASTERNAK , Andreas VERRAS , Li XIAO , Wensheng YU , Rui ZHANG , Merck Sharp & Dohme Corp.

发明人： Dane Clausen , Ping Chen , Xavier Fradera , Liangqin Guo , Yongxin Han , Shuwen He , Xianhai Huang , Joseph Kozlowski , Guoqing Li , Theodore A. Martinot , Alexander Pasternak , Andreas Verras , Li Xiao , Feng Ye , Wensheng Yu , Rui Zhang

IPC分类号： C07D231/56 , C07D491/052 , C07D231/54 , A61K31/496 , C07D401/12 , C07D401/14 , C07D413/12 , A61K31/5377 , C07D498/10 , C07D491/107 , C07D498/08 , C07D471/10 , C07D403/12 , C07D405/12 , C07D498/04 , C07D487/04 , C07D487/10 , A61K31/541 , C07D413/14

摘要： Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

64.

发明申请
NOVEL COMPOUNDS THAT ARE ERK INHIBITORS 有权
标题翻译：新的化合物是ERK抑制剂

公开(公告)号：US20160068532A1

公开(公告)日：2016-03-10

申请号：US14787280

申请日：2014-04-25

申请人： Jongwon LIM , Xianhai HUANG , Ronald D. FERGUSON , Wei ZHOU , Christopher W. BOYCE , Phieng SILIPHAIVANH , David J. WITTER , Milana M. MALETIC , Joseph A. KOZLOWSKI , Kevin J. WILSON , MERCK SHARP & DOHME CORP.

发明人： Jongwon Lim , Xianhai Huang , Ronald D. Ferguson , Wei Zhou , Christopher W. Boyce , Phieng Siliphaivanh , David J. Witter , Milana M. Maletic , Joseph A. Kozlowski , Kevin J. Wilson

IPC分类号： C07D487/04 , C07D471/14 , C07D471/04

CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D519/00

摘要： Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I).

摘要翻译： 公开了式（I）的ERK抑制剂及其药学上可接受的盐。还公开了使用式（I）化合物治疗癌症的方法。本发明还提供了包含有效量的至少一种式（I）化合物和药学上可接受的载体的药物组合物。本发明还提供一种药物组合物，其包含有效量的至少一种式（I）化合物和有效量的至少一种其它药学活性成分（例如化学治疗剂）和药学上可接受的载体。本发明还提供了在需要这种治疗的患者中抑制ERK（即，抑制ERK2的活性）的方法，包括向所述患者施用有效量的至少一种式（I）化合物。

65.

发明公开
3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS 审中-公开

公开(公告)号：US20240002359A1

公开(公告)日：2024-01-04

申请号：US18254190

申请日：2021-12-01

申请人： Stephane L. BOGEN , Ping CHEN , Dane James CLAUSSEN , Xianhai HUANG , Michael T. RUDD , Shawn P. WALSH , Lan WEI , Dexi YANG , Merck Sharp & Dohme LLC

发明人： Stephane L. Bogen , Ping Chen , Dane James Claussen , Xianhai Huang , Michael T. Rudd , Shawn P. Walsh , Lan Wei , Dexi Yang

IPC分类号： C07D401/04 , C07D417/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14

CPC分类号： C07D401/04 , C07D417/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14

摘要： The present invention is directed to 3-heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

66.

发明公开
ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY 审中-公开

公开(公告)号：US20230322785A1

公开(公告)日：2023-10-12

申请号：US18015387

申请日：2022-07-21

申请人： Christopher W. BOYCE , Thomas H. GRAHAM , Andrew J. HOOVER , Xianhai HUANG , Rognze KUANG , Jae-Hun KIM , Joseph M. KELLY , Michael Man-Chu LO , Jing SU , Dong XIAO , Xiaohong ZHU , Merck Sharp & Dohme LLC

发明人： Amjad Ali , Christopher W. Boyce , Jared N. Cumming , Duane DeMong , Thomas H. Graham , Subrahmanyam Gudipati , Andrew J. Hoover , Xianhai Huang , Rongze Kuang , Jae-Hun Kim , Joseph M. Kelly , Yeon-Hee Lim , Michael Man-Chu Lo , Jesus Moreno , Jing Su , Heping Wu , Dong Xiao , Younong Yu , Xiaohong Zhu

IPC分类号： C07D487/04 , C07K16/28 , A61P35/00

CPC分类号： C07D487/04 , A61P35/00 , C07K16/2896

摘要： The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

67.

发明申请
HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES 有权
标题翻译：取代[1,2,4]三唑[1,5-C]喹唑啉-5-胺化合物与A2A拮抗剂性质

公开(公告)号：US20150361098A1

公开(公告)日：2015-12-17

申请号：US14655648

申请日：2013-12-20

申请人： Amjad ALI , Michael Man-Chu LO , Yeon-Hee LIM , Andrew STAMFORD , Rongze KUANG , Paul TEMPEST , Younong YU , Xianhai HUANG , Timothy J. HENDERSON , Jae-Hun KIM , Christopher BOYCE , Pauline TING , Junying ZHENG , Edward METZGER , Nicolas ZORN , Dong XIAO , Gloconda GALLO , Walter WON , Heping WU , MERCH SHARP & DOHME CORP.

发明人： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Xianhai Huang , Timothy J. Henderson , Jae-Hun Kim , Christopher Boyce , Pauline Ting , Junying Zheng , Edward Metzger , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Qiaolin Deng

IPC分类号： C07D519/00 , C07D487/04

CPC分类号： C07D519/00 , C07D487/04

摘要： Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

摘要翻译： 公开了式G1（结构表示）的化合物：其中“RG3”“Rd1”至“Rd4”，“n”，“m”，“p”，“W”，“X”，“Y”和“Z “在本文中定义为哪些化合物是A2A受体的拮抗剂。本文还公开了本文所述的化合物作为A2a受体的拮抗剂的潜在治疗或预防涉及A2A受体的神经障碍和疾病的用途。本文还公开了包含这些化合物的药物组合物和这些药物组合物的用途。

68.

发明授权
Compounds that are ERK inhibitors 有权
标题翻译： ERK抑制剂的化合物

公开(公告)号：US09023865B2

公开(公告)日：2015-05-05

申请号：US14353381

申请日：2012-10-25

申请人： Jongwon Lim , Elizabeth Helen Kelley , Joey L. Methot , Hua Zhou , Alessia Petrocchi , Umar Faruk Mansoor , Christian Fischer , Brendan O'Boyle , David Joseph Guerin , Corey E. Bienstock , Christopher W. Boyce , Matthew H. Daniels , Danielle Falcone , Ronald D. Ferguson , Salem Fevrier , Xianhai Huang , Kathryn Ann Lipford , David L. Sloman , Kevin Wilson , Wei Zhou , David Witter , Milana M. Maletic , Phieng Siliphaivanh

发明人： Jongwon Lim , Elizabeth Helen Kelley , Joey L. Methot , Hua Zhou , Alessia Petrocchi , Umar Faruk Mansoor , Christian Fischer , Brendan O'Boyle , David Joseph Guerin , Corey E. Bienstock , Christopher W. Boyce , Matthew H. Daniels , Danielle Falcone , Ronald D. Ferguson , Salem Fevrier , Xianhai Huang , Kathryn Ann Lipford , David L. Sloman , Kevin Wilson , Wei Zhou , David Witter , Milana M. Maletic , Phieng Siliphaivanh

IPC分类号： C07D401/14 , A61K31/437 , C07D471/04 , C07D519/00 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06

CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00

摘要： Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

摘要翻译： 公开了式（1）的ERK抑制剂及其药学上可接受的盐。还公开了使用式（1）的化合物治疗癌症的方法。

69.

发明申请
PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES 有权
标题翻译：哌嗪取代[1,2,4]三唑[1,5-C]喹唑啉-5-胺化合物，具有A2A拮抗剂性质

公开(公告)号：US20160194330A1

公开(公告)日：2016-07-07

申请号：US14655572

申请日：2013-12-20

申请人： Amjad ALI , Michael Man-Chu LO , Yeon-Hee LIM , Andrew STAMFORD , Rongze KUANG , Paul TEMPEST , Younong YU , Michael BERLIN , Pauline TING , Gang ZHOU , Tao YU , Christopher BOYCE , Joseph Michael KELLY , Jayaram TAGAT , Junying ZHENG , Xianhai HUANG , Wei ZHOU , Jae-Hun KIM , Nicolas ZORN , Dong XIAO , Gioconda V. GALLO , Walter WON , Heping WU , Rajan ANAND , MERCK SHARP & DOHME CORP.

发明人： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC分类号： C07D487/04 , C07D487/18 , C07D487/08 , C07D513/04

CPC分类号： C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

摘要： Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

摘要翻译： 公开了式A化合物（结构表示），其中“RG1”，“RG2a”，“RG4”，“RG5”，“MG1”，“n”和“m”在本文中定义为哪些化合物是A2A受体的拮抗剂。本文还公开了本文所述的化合物作为A2a受体的拮抗剂的潜在治疗或预防涉及A2A受体的神经障碍和疾病的用途。本文还公开了包含这些化合物的药物组合物和这些药物组合物的用途。